Table 2.

CF-Related Complications during the Index PEx Year Stratified by Prior-Year PEx.

Prior-Year PEx
	None (N=8,098)	One (N=2,457)	Two (N=1,466)	Three (N=762)	≥ Four (N=796)	All (N=13,579)
Allergic Bronchopulmonary Aspergillosis (ABPA), N (%)
	455 (5.6%)	190 (7.7%)	135 (9.2%)	76 (10.0%)	95 (11.9%)	951 (7.0%)
Asthma, N (%)
	2185 (27.0%)	739 (30.1%)	499 (34.0%)	241 (31.6%)	251 (31.5%)	3915 (28.8%)
Massive Hemoptysis, N (%)
	99 (1.2%)	42 (1.7%)	37 (2.5%)	29 (3.8%)	33 (4.1%)	240 (1.8%)
Pneumothorax, N (%)
	34 (0.4%)	15 (0.6%)	15 (1.0%)	7 (0.9%)	12 (1.5%)	83 (0.6%)
Sinus Disease, N (%)
	2553 (31.5%)	825 (33.6%)	548 (37.4%)	296 (38.8%)	294 (36.8%)	4516 (33.3%)
Hepatic Steatosis, N (%)
	33 (0.4%)	8 (0.3%)	5 (0.3%)	4 (0.5%)	7 (0.9%)	57 (0.4%)
Gastroesophageal Reflux Disease (GERD), N (%)
	2386 (29.5%)	848 (34.5%)	548 (37.4%)	319 (41.9%)	350 (44.0%)	4451 (32.8%)
Glucose Tolerance, N (%)*
Normal	5838 (72.1%)	1596 (65.0%)	878 (59.9%)	410 (53.8%)	346 (43.5%)	9068 (66.8%)
Impaired	736 (9.1%)	251 (10.2%)	133 (9.1%)	94 (12.3%)	87 (10.9%)	1301 (9.6%)
Diabetes	1461 (18.0%)	582 (23.7%)	434 (29.6%)	247 (32.4%)	340 (42.7%)	3064 (22.6%)
NA	63 (0.8%)	28 (1.1%)	21 (1.4%)	11 (1.4%)	23 (2.9%)	146 (1.1%)
Liver Disease, Cirrhosis, N (%)
	184 (2.3%)	76 (3.1%)	50 (3.4%)	34 (4.5%)	46 (5.8%)	390 (2.9%)
Liver Disease, Non-Cirrhosis, N (%)
	426 (5.3%)	172 (7.0%)	106 (7.2%)	66 (8.7%)	60 (7.5%)	830 (6.1%)
Liver Disease, Other, N (%)
	192 (2.4%)	39 (1.6%)	24 (1.6%)	16 (2.1%)	14 (1.8%)	285 (2.1%)
Pancreatitis, N (%)
	121 (1.5%)	39 (1.6%)	28 (1.9%)	16 (2.1%)	34 (4.3%)	238 (1.8%)
Hypertension, N (%)
	176 (2.2%)	67 (2.7%)	51 (3.5%)	39 (5.1%)	41 (5.2%)	374 (2.8%)

^*-column percentages; NA= covariate status not available